CNSP Since 2019 Annualized Return and Average Annual Return

CNSP Average Annual Return Chart Since 2019
Growth of $10,000.00
Without Dividends Reinvested Into CNSP

Also see:
• CNSP stock yearly return 2020
• CNSP stock yearly return 2021
• CNSP stock yearly return 2022
• CNSP stock yearly return 2023
• CNSP stock yearly return 2024
• CNSP stock yearly return 2025
• CNSP YTD return
Average Annual Return Benchmarks
Compare CNSP average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
CNSP Share Performance
CNSP Average Annual Return Table Since 2019
Start date: 11/11/2019
End date: 05/08/2026
Start price/share: $3,825,000.00
End price/share: $7.29
Dividends collected/share: $0.00
Total return: -100.00%
CNSP Average Annual Return: -86.86%
Starting investment: $10,000.00
Ending investment: $0.02
Years: 6.49


CNSP average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). Co.'s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The CNSP average annual return since 2019 is shown above.

The Average Annual Return on the CNSP average annual return since 2019 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether CNSP average annual return since 2019 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the CNSP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
CNSP Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree CNSP Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
CNS Pharmaceuticals (CNSP) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CNTX Average Annual Return
COCP Average Annual Return
CODX Average Annual Return
COGT Average Annual Return
COLL Average Annual Return
COM Average Annual Return
CON Average Annual Return
COO Average Annual Return
COR Average Annual Return
CORT Average Annual Return
More Healthcare companies »
 

CNSP Average Annual Return Since 2019 | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.